Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 1
1964 2
1965 3
1968 2
1969 3
1970 2
1978 1
1979 1
1980 1
1983 1
1985 2
1986 1
1988 1
1989 1
1990 1
1995 1
1997 1
2009 1
2012 2
2013 1
2014 1
2017 1
2019 1
2021 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study.
Kühn T, Banys-Paluchowski M, Ditsch N, Stickeler E, Hauptmann M, Schroth J, Karadeniz Cakmak G, Hahn M, Thill M, Reimer T, Fröhlich S, Schmidt E, Wihlfahrt K, Berger T, Basali T, Ruf F, Rief A, Lux MP, Kolberg HC, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Pinto D, Peintinger F, Schlichting E, Nina H, Valiyeva Qanimat H, Vanhoeij M, Rebaza LP, Aktas Sezen B, Jursik K, Kadayaprath G, Dostalek L, Kothari A, Perhavec A, Ivanov T, Zippel D, Thongvitokomarn S, Gurleyik MG, Watermann D, Porpiglia M, Lebeau A, Di Micco R, Gentilini OD, de Boniface J, Hartmann S; AXSANA Study Group. Kühn T, et al. Br J Surg. 2025 Sep 2;112(9):znaf180. doi: 10.1093/bjs/znaf180. Br J Surg. 2025. PMID: 40966675
Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655).
Hartmann S, Banys-Paluchowski M, Berger T, Ditsch N, Stickeler E, de Boniface J, Gentilini OD, Schroth J, Karadeniz Cakmak G, Rubio IT, Gasparri ML, Kontos M, Bonci EA, Niinikoski L, Murawa D, Kadayaprath G, Pinto D, Peintinger F, Schlichting E, Dostalek L, Nina H, Valiyeva H, Vanhoeij M, Perhavec A, Zippel D, Rebaza LP, Thongvitokomarn S, Fröhlich S, Ruf F, Rief A, Wihlfahrt K, Basali T, Thill M, Lux MP, Loibl S, Kolberg HC, Blohmer JU, Hahn M, Gurleyik MG, Porpiglia M, Gunay S, Zetterlund L, Kuehn T; AXSANA Study Group. Hartmann S, et al. Eur J Surg Oncol. 2025 Sep;51(9):110253. doi: 10.1016/j.ejso.2025.110253. Epub 2025 Jun 25. Eur J Surg Oncol. 2025. PMID: 40587927 Free article.
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.
Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching PA, Harbeck N, Langanke D, Uhrig S, Häberle L, Fischer D, Hein A, Fehm TN, Goossens C, Terhaag J, Heilenkötter U, Dall P, Rudlowski C, Wuerstlein R, Aydogdu M, Keyver-Paik MD, Hammerle C, Deuerling N, Stickeler E, Aktas B, Belleville E, Thoma M, Ditsch N, Baila Y, Roos C, Mann C, Iuliano C, Brucker SY, Schneeweiss A, Hartkopf AD. Müller V, et al. Among authors: langanke d. Breast. 2025 Jun;81:104458. doi: 10.1016/j.breast.2025.104458. Epub 2025 Mar 22. Breast. 2025. PMID: 40147402 Free PMC article.
Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.
Banys-Paluchowski M, Hartmann S, Basali T, Gasparri ML, de Boniface J, Gentilini OD, Cakmak GK, Ditsch N, Stickeler E, Schlichting E, Rubio I, Peintinger F, Untch M, Mau C, Federspiel FK, Bucher S, Ramaker K, Paluchowski P, Bauer L, Riemer S, Langanke D, Leuf TD, Schnabel J, von Abel E, Solbach C, Ovalle SC, Hilmer K, Bjelic-Radisic V, Stahl N, Sanchez-Mendez JI, Hagen V, Hansen MH, Krawczyk N, Sezen BA, Jursik K, Thill M, Kolberg HC, Reimer T, Ruf F, Wihlfahrt K, Rief A, Berger T, Schmidt E, Tauber N, Fröhlich S, Kühn T. Banys-Paluchowski M, et al. Among authors: langanke d. Breast Cancer Res Treat. 2025 May;211(1):203-211. doi: 10.1007/s10549-025-07635-4. Epub 2025 Feb 20. Breast Cancer Res Treat. 2025. PMID: 39976867
[Premature births].
Krauss A, Langanke D, Tosetti K. Krauss A, et al. Among authors: langanke d. Zentralbl Gynakol. 1969 May 17;91(20):648-55. Zentralbl Gynakol. 1969. PMID: 5372566 German. No abstract available.
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer.
Lüftner D, Banys-Paluchowski M, Hartkopf AD, Hörner M, Janni W, Langanke D, Müller V, Schneeweiss A, Schmidt M, Thill M, Untch M, Wöckel A, Höllrich L, Kreuzeder J, Marx A, Meinzinger J, Regus-Leidig H, Roos C, Wohlgemuth H, Sussmann S, Fasching PA. Lüftner D, et al. Among authors: langanke d. Geburtshilfe Frauenheilkd. 2025 Apr 4;85(6):599-610. doi: 10.1055/a-2561-6640. eCollection 2025 Jun. Geburtshilfe Frauenheilkd. 2025. PMID: 40510406 Free PMC article.
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Kunze CA, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM; Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators. Coombes RC, et al. JAMA Oncol. 2021 Sep 1;7(9):1291-1301. doi: 10.1001/jamaoncol.2021.2193. JAMA Oncol. 2021. PMID: 34264305 Free PMC article. Clinical Trial.
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Untch M, et al. Lancet Oncol. 2012 Feb;13(2):135-44. doi: 10.1016/S1470-2045(11)70397-7. Epub 2012 Jan 17. Lancet Oncol. 2012. PMID: 22257523 Clinical Trial.
39 results